It can be seen that in systemic therapy for RCC, the research hotspots have shifted from traditional immunotherapy (such as interferon α and interleukin-2) to targeted drugs (such as sunitinib and sorafenib) in recent years, and the major type of research was an open-label phase III clinical trial (Fig. 10). This evidence concerns the gene IL2 and renal cell adenocarcinoma.